검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 21일
현재 선택: 3개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | tirzepatide (Mounjaro / Zepbound, Mounjaro, Zepbound, LY3298176) Eli Lilly·GLP-1 / GIP receptor HbA1c ↓2.4%·t½ 6 h | semaglutide (Ozempic / Wegovy, GLP-1, Wegovy, NN9535) Novo Nordisk·GLP-1 receptor Weight ↓14.9%·t½ ~1 week (SC) | administered by PDS290 pen-injector (Semaglutide, Semaglutide (administered by PDS290 pen-injector)) Prof. Dr. Martin Wabitsch·Monogenic Obesity 1 trials |
|---|---|---|---|
Overview Program | Mounjaro / Zepbound (tirzepatide) | Ozempic / Wegovy (semaglutide) | Semaglutide (administered by PDS290 pen-injector) |
Overview Company | Eli Lilly | Novo Nordisk | Prof. Dr. Martin Wabitsch |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | GLP-1 / GIP receptor | GLP-1 receptor | Monogenic Obesity |
Overview Indication | Type 2 diabetes, chronic weight management | Type 2 diabetes, chronic weight management, CV risk reduction (T2D) | Monogenic Obesity |
Overview Phase | APPROVED | APPROVED | PRECLINICAL |
Overview Status | APPROVED | APPROVED | RECRUITING |
MoA Mechanism | Dual GIP/GLP-1R agonism → enhanced insulin secretion, weight loss, lipolysis | GLP-1R agonism → glucose-dependent insulin secretion, delayed gastric emptying, central satiety | — |
MoA Biomarker | HbA1c, body weight, triglycerides | HbA1c, body weight, waist circumference | — |
PK/PD Half-life | 6 h | ~1 week (SC) | — |
PK/PD Species | Mouse | Mouse, HbA1c, fasting glucose, weight | — |
PK/PD Animal (cat.) | Mouse | Mouse | — |
PK/PD Experiment | pharmacokinetic | pharmacokinetic | — |
Toxicology Species | Mouse, Rat | NHP, Mouse, Rat | — |
Toxicology Animal (cat.) | Mouse, Rat | NHP | — |
Toxicology Major finding | — | Thyroid C-cell tumors in rodents (class warning); GI AEs in clinic | Boxed Warning, Warnings and Precautions ( 5 |
Toxicology CRS | — | N/A | — |
Clinical Primary efficacy | HbA1c ↓2.4% | Weight ↓14.9% | — |
Clinical ORR | HbA1c ↓2.4% (SURPASS-2 vs semaglutide 1 mg) | Weight ↓14.9% vs placebo (STEP 1) | — |
Clinical PFS | Weight ↓20% at 72 wk (SURMOUNT-1) | MACE benefit in SELECT (obesity + CVD) | — |
Clinical Result source | SURPASS-2 / SURMOUNT-1 | STEP 1 / SELECT | — |
Clinical Data Tier / Score | S · 77 | B · 75 | C · 3 |
Clinical Program phase | APPROVED | APPROVED | PRECLINICAL |
Clinical Dose / schedule | — | q1w SC (titrated) or oral daily | — |
Clinical Clinical sync | 2026년 7월 20일 (2일 전) | 2026년 7월 20일 (2일 전) | 2026년 5월 22일 (60일 전 · 갱신 권장) |
검색으로 10,000+ 프로그램 중 최대 5개를 골라 PK/PD · 독성 · 임상을 나란히 비교합니다. · 다음 갱신 D-13 · 마지막 7월 21일
현재 선택: 3개 · 임상 갱신 필요 1개
프로그램 상세에서 관심 등록 후 2개 이상 모으면 여기서 한 번에 비교할 수 있습니다.
표가 넓으면 좌우로 스크롤하세요. 핵심 비교 모드에서는 중요 항목만 표시됩니다.
| 항목 | tirzepatide (Mounjaro / Zepbound, Mounjaro, Zepbound, LY3298176) Eli Lilly·GLP-1 / GIP receptor HbA1c ↓2.4%·t½ 6 h | semaglutide (Ozempic / Wegovy, GLP-1, Wegovy, NN9535) Novo Nordisk·GLP-1 receptor Weight ↓14.9%·t½ ~1 week (SC) | administered by PDS290 pen-injector (Semaglutide, Semaglutide (administered by PDS290 pen-injector)) Prof. Dr. Martin Wabitsch·Monogenic Obesity 1 trials |
|---|---|---|---|
Overview Program | Mounjaro / Zepbound (tirzepatide) | Ozempic / Wegovy (semaglutide) | Semaglutide (administered by PDS290 pen-injector) |
Overview Company | Eli Lilly | Novo Nordisk | Prof. Dr. Martin Wabitsch |
Overview Modality | ANTIBODY | ANTIBODY | ANTIBODY |
Overview Target | GLP-1 / GIP receptor | GLP-1 receptor | Monogenic Obesity |
Overview Indication | Type 2 diabetes, chronic weight management | Type 2 diabetes, chronic weight management, CV risk reduction (T2D) | Monogenic Obesity |
Overview Phase | APPROVED | APPROVED | PRECLINICAL |
Overview Status | APPROVED | APPROVED | RECRUITING |
MoA Mechanism | Dual GIP/GLP-1R agonism → enhanced insulin secretion, weight loss, lipolysis | GLP-1R agonism → glucose-dependent insulin secretion, delayed gastric emptying, central satiety | — |
MoA Biomarker | HbA1c, body weight, triglycerides | HbA1c, body weight, waist circumference | — |
PK/PD Half-life | 6 h | ~1 week (SC) | — |
PK/PD Species | Mouse | Mouse, HbA1c, fasting glucose, weight | — |
PK/PD Animal (cat.) | Mouse | Mouse | — |
PK/PD Experiment | pharmacokinetic | pharmacokinetic | — |
Toxicology Species | Mouse, Rat | NHP, Mouse, Rat | — |
Toxicology Animal (cat.) | Mouse, Rat | NHP | — |
Toxicology Major finding | — | Thyroid C-cell tumors in rodents (class warning); GI AEs in clinic | Boxed Warning, Warnings and Precautions ( 5 |
Toxicology CRS | — | N/A | — |
Clinical Primary efficacy | HbA1c ↓2.4% | Weight ↓14.9% | — |
Clinical ORR | HbA1c ↓2.4% (SURPASS-2 vs semaglutide 1 mg) | Weight ↓14.9% vs placebo (STEP 1) | — |
Clinical PFS | Weight ↓20% at 72 wk (SURMOUNT-1) | MACE benefit in SELECT (obesity + CVD) | — |
Clinical Result source | SURPASS-2 / SURMOUNT-1 | STEP 1 / SELECT | — |
Clinical Data Tier / Score | S · 77 | B · 75 | C · 3 |
Clinical Program phase | APPROVED | APPROVED | PRECLINICAL |
Clinical Dose / schedule | — | q1w SC (titrated) or oral daily | — |
Clinical Clinical sync | 2026년 7월 20일 (2일 전) | 2026년 7월 20일 (2일 전) | 2026년 5월 22일 (60일 전 · 갱신 권장) |
추천 비교
추천 비교